[Form 3] Tenon Medical, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Tenon Medical's Chief Innovation Officer, Wyatt D. Geist, filed a Form 3 reporting beneficial ownership related to an 08/01/2025 event. He directly holds 138,114 common shares (noted as subject to a vesting schedule and non-transferable) and has an indirect interest of 350,765 shares through SiVantage, Inc. SiVantage owns 710,300 shares and Geist holds a 49.38% equity interest in that company.

Positive

• Officer role disclosed: Reporting person identified as Chief Innovation Officer of Tenon Medical.
• Clear ownership breakdown: Direct 138,114 shares and indirect interest of 350,765 shares via SiVantage (SiVantage holds 710,300 shares).
• Equity stake in affiliate disclosed: Reporting person owns 49.38% of SiVantage, providing transparency on indirect holdings.

Negative

• Direct shares are restricted: The 138,114 directly held shares are noted as subject to a vesting schedule and non-transferable, limiting immediate liquidity.

Insights

Securities Analyst

TL;DR: Routine insider filing disclosing a combined 488,879 share interest; limited immediate market impact.

The Form 3 documents a standard Section 16 disclosure: 138,114 shares held directly by the reporting person (subject to vesting and non-transferability) and an indirect interest of 350,765 shares via SiVantage, Inc. The filing states SiVantage holds 710,300 shares and that the reporting person owns 49.38% of SiVantage. This is a factual record of insider ownership without additional transactions or derivative positions reported.

Corporate Governance Expert

TL;DR: Disclosure confirms officer-level ownership and a material indirect stake through an affiliate, enhancing transparency.

The report identifies Wyatt D. Geist as an officer (Chief Innovation Officer) and provides clear ownership breakdowns: direct holdings of 138,114 common shares and an indirect interest of 350,765 shares via SiVantage, which holds 710,300 shares and is 49.38% owned by the reporting person. The filing documents governance-related ownership ties between the executive and an affiliated entity.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Geist Wyatt D.

(Last) (First) (Middle)

104 COOPER COURT

(Street)

LOS GATOS CA 95032

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/01/2025

3. Issuer Name and Ticker or Trading Symbol
Tenon Medical, Inc. [ TNON ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Innovation Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock(1)	138,114	D
Common Stock(2)	350,765	I	By SiVantage, Inc.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Subject to a vesting schedule and non-transferable.

2. Reflects the reporting person's indirect interest in 710,300 shares owned by SiVantage, Inc., a corporation in which the reporting person has a 49.38% equity interest.

	/s/ Wyatt Giest	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Wyatt D. Geist disclose in the Tenon Medical (TNON) Form 3 filing?

He disclosed direct ownership of 138,114 common shares and an indirect interest of 350,765 shares via SiVantage, Inc.

When is the event date reported on the Form 3 for TNON?

The Date of Event Requiring Statement is 08/01/2025.

How much of SiVantage does the reporting person own according to the filing?

The filing states the reporting person holds a 49.38% equity interest in SiVantage, Inc.

How many shares does SiVantage, Inc. own as reported?

SiVantage, Inc. is reported to own 710,300 common shares of Tenon Medical.

Are any derivative securities reported in this Form 3 for TNON?

No derivative securities (puts, calls, warrants, options, or convertible securities) are listed in Table II of the filing.

Is there any restriction noted on the directly held TNON shares?

Yes, the 138,114 directly held shares are noted as subject to a vesting schedule and non-transferable.